Cue Biopharma Announces Positive Phase 1 Data for CUE-101 and CUE-102 at SITC 2024
核心洞察
CUE-101 combined with pembrolizumab shows a 46% objective response rate and 91.3% 12-month overall survival in first-line HPV+ recurrent/metastatic head and neck squamous cell carcinoma (搜索) patients.
In first-line patients with low PD-L1 expression, CUE-101 and pembrolizumab achieved a 50% objective response rate, indicating potential efficacy in challenging-to-treat populations.
CUE-102 monotherapy demonstrates a 67% overall disease control rate in late-stage pancreatic cancer (搜索), including an unconfirmed partial response with a 40% tumor burden reduction.
Cue Biopharma presented updated data from its Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024), showcasing promising results in head and neck cancer and WT1 (搜索)-positive cancers. The data highlight the potential of these Immuno-STAT biologics to selectively engage and modulate disease-specific T cells for cancer treatment.
CUE-101 in Head and Neck Cancer
In the expansion portion of the Phase 1 trial, CUE-101 at the recommended Phase 2 dose (RP2D) of 4mg/kg in combination with pembrolizumab in first-line HPV+ recurrent/metastatic head and neck squamous cell carcinoma (搜索) (R/M HNSCC) patients demonstrated an objective response rate (ORR) of 46% and an overall disease control rate (DCR) of 75% in patients with combined positive score (CPS) ≥1. This compares favorably to the 19% ORR observed with pembrolizumab alone in the historical KEYNOTE-048 trial. The results included one complete response (CR) and 10 partial responses (PR), along with seven durable stable diseases (DSD) of >12 weeks.
Survival metrics also showed improvement, with a 12-month overall survival (OS) of 91.3% compared to 51% in the historical KEYNOTE-048 trial, and a median overall survival (mOS) of 21.8 months compared to 12.3 months in the KEYNOTE-048 trial. Notably, an ORR of 50% was observed in patients with PD-L1 CPS 1-19.
As a monotherapy in second line and beyond (2L+) patients, CUE-101 showed a mOS of 20.8 months, which is longer than the historical mOS of 7.5 and 8.4 months reported in historical third-party 2L R/M HNSCC trials: CheckMate 141 and KEYNOTE-040, respectively.
Christine H. Chung, M.D., Department Chair, Head and Neck-Endocrine Oncology, Moffitt Cancer Center, commented, "The therapeutic responses observed with CUE-101 and pembrolizumab are very promising...The latest results highlight the potential of CUE-101 to improve response rates and quality of life for this patient population."
CUE-102 in WT1-Positive Cancers
Data from the completed dose escalation and ongoing dose expansion parts of the Phase 1 clinical trial of CUE-102 showed a 67% overall DCR in late-stage pancreatic cancer (搜索) patients treated with CUE-102 at 2 and 4mg/kg. This included an unconfirmed partial response (PR) with a 40% decrease in tumor burden. The trial also provided evidence of selective stimulation and expansion of WT1 (搜索)-specific CD8 T cells, without a significant increase in total numbers of non-specific CD8 T cells. No dose-limiting toxicities occurred in patients treated during the dose escalation phase at doses ranging between 1-8mg/kg of CUE-102.
About CUE-101 and CUE-102
CUE-101 is designed to activate and expand HPV16 (搜索) tumor-specific T cells by presenting the HPV E7 protein to the HPV-specific T cell receptor. CUE-102 is designed to activate and expand Wilms’ Tumor 1 (WT1 (搜索))-specific T cells by presenting the WT1 peptide to the WT1- specific T cell receptor. Both are part of Cue Biopharma’s CUE-100 series of interleukin 2 (IL-2)-based biologics.
Matteo Levisetti, M.D., chief medical officer of Cue Biopharma, stated, "The CUE-102 data further demonstrates the mechanism of action of Immuno-STAT biologics to activate and expand tumor-specific T cells, as well as its translation into evidence of clinical benefit. The versatility of the Immuno-STAT platform holds significant potential for treating a variety of cancers."